Alexander disease (AxD) is a primary disorder of astrocytes caused by dominant mutations in the gene for glial fibrillary acidic protein (GFAP). These mutations lead to protein aggregation and formation of Rosenthal fibers, complex astrocytic inclusions that contain GFAP, vimentin, plectin, ubiquitin, Hsp27 and aB-crystallin. The small heat shock protein aB-crystallin (Cryab) regulates GFAP assembly, and elevation of Cryab is a consistent feature of AxD; however, its role in Rosenthal fibers and AxD pathology is not known. Here, we show in AxD mouse models that loss of Cryab results in increased mortality, whereas elevation of Cryab rescues animals from terminal seizures. When mice with Rosenthal fibers induced by over-expression of GFAP are crossed into a Cryab-null background, over half die at 1 month of age. Restoration of Cryab expression through the GFAP promoter reverses this outcome, showing the effect is astrocyte-specific. Conversely, in mice engineered to express both AxD-associated mutations and elevated GFAP, which despite natural induction of Cryab also die at 1 month, transgenic over-expression of Cryab results in a markedly reduced CNS stress response, restores expression of the glutamate transporter Glt1 (EAAT2) and protects these animals from death. In its most common form, AxD is a devastating neurodegenerative disease, with early onset, characterized by seizures, spasticity and developmental delays, ultimately leading to death. Cryab plays a critical role in tempering AxD pathology and should be investigated as a therapeutic target for this and other diseases with astropathology.
INTRODUCTION
Alexander disease (AxD) is a rare and typically fatal neurodegenerative disorder of childhood caused by mutations in the astrocyte-specific intermediate filament glial fibrillary acidic protein (GFAP) (1, 2) . Common initial symptoms include seizures and spasticity, which in the early onset form, progress to death within 3 -4 years. Although AxD usually manifests during infancy, GFAP mutations are also responsible for less severe cases with juvenile or adult onset (3), but no specific genotype -phenotype relationships have yet been identified. Three obvious hot spots for mutations exist, with approximately half of all patients affected at R79, R239 or R416, but many other mutations are distributed throughout the rod and tail domains of the protein (3) . In some cases, the same mutation (i.e. R416W) is associated with all three forms of the disease.
The consistent pathological hallmark of AxD is the formation of cytoplasmic protein aggregates within astrocytes known as Rosenthal fibers. In addition to GFAP, these aggregates contain many other components, including vimentin, the cytoskeletal crosslinker plectin (4), ubiquitin and the small stress proteins Hsp25 and aB-crystallin (5, 6) . As with other protein aggregation disorders of the central nervous system (7) , the question of whether the Rosenthal fibers are toxic or protective has not yet been resolved.
Although the genetic basis for AxD is now firmly established, little is known regarding the mechanisms by which GFAP mutations lead to disease (8, 9) . Using mouse models, we have shown that Rosenthal fibers can originate from either expression of mutant protein or over-expression of wild-type protein, and that elevation in total levels of GFAP may be a critical element in pathogenesis (10) (11) (12) . GFAP mutations are dominant, generating protein with a toxic gain of function, but etiologically it is also possible that astrocyte dysfunction occurs in part due to depletion and consequent loss of function in other cellular elements, such as aB-crystallin (Cryab). Rosenthal fibers are associated with shifts in the equilibrium of both GFAP and Cryab from the soluble to insoluble protein pool (6, 13) .
Cryab was first identified in the lens, but is now viewed as part of a multi-gene family of widely expressed small heat shock proteins in which Cryab has been given the designation Hspb5 (14) . Functionally, Cryab acts as a chaperone (15 -17) and is normally expressed in several tissues outside of the eye even in the absence of stress (18, 19) . Cryab associates with intermediate filaments, especially type III filaments such as vimentin (20) , desmin (21) and GFAP (22) , where it regulates assembly and assists intermediate filaments in recovery from stress by preventing untimely filament -filament interactions that would otherwise lead to aggregation. Recently, Ghosh et al. (23) identified six distinct regions within human CRYAB that are preferential binding sites for human GFAP.
Cryab also negatively regulates apoptosis through multiple mechanisms (24 -26) , maintains redox homeostasis (27) and binds to the 20S proteasome, where it may facilitate degradation of misfolded proteins (28, 29) . In the absence of Cryab, knockout mice show normal lens development and age-related degeneration of skeletal muscle, but otherwise have no overt phenotype. A recent study, however, show Cryab 2/2 mice to be more susceptible to experimental autoimmune encephalomyelitis (EAE) with an increase in inflammation and glial apoptosis (30) .
Although Cryab is normally expressed at low levels in the brain, its induction in several neurodegenerative diseases, abundance in Rosenthal fibers and apparent role in regulating interactions of intermediate filament subunits led us to consider whether it could play an active role in the pathogenesis of AxD. Studies have shown that increased levels of Cryab solublize GFAP and decrease aggregation in vitro (20, 22, 31) . By genetically manipulating levels of Cryab in mouse models of AxD, we find that deficiency of Cryab exacerbates the AxD phenotype, causing death in lines that are normally viable. In contrast, enhancing Cryab beyond naturally occurring levels rescues AxD mice from the otherwise lethal effects of GFAP mutation and excess.
RESULTS

Loss of Cryab in GFAP transgenic mice decreases survival
To determine the impact of Cryab on Rosenthal fiber formation and AxD pathology, we crossed transgenic mice expressing wild-type human GFAP (line Tg73.7 (10), hereafter referred to as GFAP Tg ) with Cryab 2/2 knockout mice. The resulting GFAP Tg ;Cryab 2/2 animals still form ubiquitinated astrocytic protein aggregates (Fig. 1A and B) , which under electron microscopy consist of electron dense osmiophilic structures surrounded by swirls of intermediate filaments, consistent with Rosenthal fibers (32) (Fig. 1C) . Typically, GFAP Tg mice have ,10% mortality at 30 days of age, whereas in the context of Cryab deficiency, two-thirds of Cryab 2/2 animals and one-third of Cryab þ/2 animals die at a median age of 32 days (Fig. 1D ). Although our results show that Cryab is not necessary for Rosenthal fiber formation, the increased number of mice showing lethality at this age clearly demonstrates the importance of Cryab in maintaining viability for the GFAP Tg model. In contrast to GFAP Tg mice, heterozygous GFAP þ/R236H knock-in animals with an AxD-associated mutation (equivalent to R239H in human GFAP) remain viable in the Cryab 2/2 background.
Transgenic expression of Cryab in astrocytes restores survival proportions for GFAP Tg mice
To determine whether lethality in the GFAP Tg ;Cryab
animals is a result of the loss of Cryab in astrocytes, we generated transgenic mice with the Cryab gene under the control of the human GFAP promoter to target expression to astrocytes ( Fig. 2A) . Several transgenic lines with varying levels of expression were produced (Fig. 2B) ;Cryab Tg mice also showed a reduction in the insoluble fraction of GFAP; however, there were no significant changes in solubility in GFAP
;Cryab Tg mice (Fig. 3D ). Increased Cryab may be able to compensate for the high levels of wild-type GFAP in the GFAP Tg mice, whereas the mutant forms of GFAP are likely more resistant to dissolution (13) .
Cryab
Tg reduces the stress response and restores Glt1 expression in GFAP Tg ;GFAP 1/R236H mice
The transcription factor Nrf2 (Nfe2l2) regulates the expression of phase II detoxification genes including peroxiredoxins, oxidoreductases such as Nqo1, and genes involved in the glutathione and thioredoxin systems through the anti-oxidant response element (ARE). We showed previously that GFAP Tg and GFAP þ/R236H mice each have dramatic increases in ARE-induced activity and a corresponding elevation of Nrf2-regulated gene transcripts (11, 12) . GFAP Tg ;GFAP þ/ R236H mice demonstrate over a 5-fold increase in the expression of both Nrf2 and its target gene Nqo1 ( Fig. 4A and B). The addition of the Cryab transgene reduced both Nrf2 and Nqo1 transcript levels by .60%, and to near that of wild-type in the GFAP þ/R236H and GFAP Tg mice separately. We have recently shown that adult GFAP þ/R236H mice have reduced levels of the glutamate transporter Glt1 (Slc1a2, EAAT2; R. Tian, X. Wu, T.L. Hagemann, A.A. Sosunov, Z. Su, T.F. Franke, P.B. Fisher, A. Messing, G.M. McKhann, J.E. Goldman, in preparation) and are more susceptible to kainate-induced seizures (12) . Since astrocytes are responsible for regulating synaptic glutamate uptake primarily through Glt1, and seizures can be induced by elevated glutamate and excitotoxicity (33), we measured hippocampal Glt1 expression in GFAP Tg ;GFAP þ/R236H mice. These animals show a 70% reduction in Glt1 expression ( ;Cryab Tg animals show nearly a 2-fold increase in Glt1 transcripts (P ¼ 0.0182). Glt1 protein shows a similar pattern with restoration of expression to near that of wild-type ( Fig. 4D) , demonstrating a potential mechanism for the rescue effect and increased survival.
Elevated Cryab reduces GFAP accumulation in GFAP Tg mice and reduces the stress response in both GFAP transgenic and mutant mice
To further detail the role of Cryab in AxD pathology in older animals, we analyzed Rosenthal fiber distribution and the R236H mice showed no obvious differences in Rosenthal fiber distribution when crossed with the Cryab Tg line, correlating with the lack of effect on GFAP solubility.
To characterize and quantify the effect of increased Cryab expression on the stress response in AxD mice, a reporter transgene for Nrf2 activation was introduced consisting of the ARE driving the human placental alkaline phosphatase (hPAP) gene. With increased Cryab expression, the stress response is significantly decreased by almost 90% in both GFAP Tg and GFAP þ/R236H mice at 6 weeks of age (Fig. 5E ). Histological staining for the alkaline phosphatase reporter shows reduced activity in most regions including cortex, subpial regions, corpus callosum, midbrain, cerebellum, olfactory bulb and hippocampus ( Fig. 5F-I ).
DISCUSSION
The small heat shock protein aB-crystallin is a multi-tasking chaperone with important roles in cytoskeletal assembly, protein turnover, redox homeostasis and apoptosis. Cryab provides chaperone functions for cytoskeletal and other proteins (5, 6, (34) (35) (36) . Whether Cryab is a critical determinant of cellular response to injury, and whether its expression could be manipulated for therapeutic benefit in any of these diseases,
is not yet known. Large molecular chaperones such as Hsp70 are often elevated in protein misfolding disorders, and expression levels affect aggregate toxicity (34,37), but Hsp70 is not induced, nor is it a component of Rosenthal fibers in AxD models (6,10). Our results suggest that for mouse models of the GFAP-mediated disorder, AxD, aB-crystallin plays an important role in determining disease severity. Loss of Cryab alone does not cause an obvious neurological phenotype (38) , but recent studies show that Cryab null mice are more susceptible to EAE, and that astrocytes cultured from these animals show increased cell death and have elevated MAP kinase and NF-kB activation in response to TNF (30) . In contrast, a protective effect of enhanced Cryab expression has previously been studied in the heart, where reduction in oxidative stress protected cardiomyocytes from ischemia reperfusion injury (39) .
In our AxD model that over-expresses wild-type GFAP, absence of Cryab leads to increased mortality, but our knock-in models that express a disease-associated mutation in GFAP do not show the same effect. Although both lines of mice have elevations in total GFAP, the levels in the wildtype over-expressers are much higher, which may place them at higher risk. Clearly, the stress response as measured by the ARE-reporter is higher and more widely distributed in the GFAP Tg mice. It should be noted that the deletion engineered to create the Cryab 2/2 knockout mice also affected the adjacent Hspb2 gene (38) , and it is formally possible that some of the mortality we observe reflects loss of Hspb2 rather than Cryab. However, Hspb2 expression is not normally detected ;Cryab Tg mice (I) and absent altogether in some regions (6 weeks of age shown).
Human Molecular Genetics, 2009, Vol. 18, No. 7 1195 in brain (40, 41) , and it is not inducible under the same conditions that induce aB-crystallin (42) . In addition, the ability of GFAP-driven expression of aB-crystallin to rescue the GFAP Tg ;Cryab 2/2 animals from death demonstrates that it is the loss of Cryab, and not Hspb2, that is most critical.
Both GFAP Tg and GFAP þ/R236H mice demonstrate a marked secondary stress response as evidenced by increased expression of the transcription factor Nrf2 and several stressresponsive genes regulated by Nrf2 through the ARE, including Nqo1 and other genes involved in moderating oxidative toxicity (11, 12) . Here, we show that increased expression of Cryab dramatically reduces this stress response in both the GFAP transgenic and mutant animals as well as in the combination GFAP Tg ; GFAP þ/R236H mice. As a chaperone, Cryab may alleviate stress by stabilizing GFAP and the cytoskeleton (20, 22) or by promoting proteasomal degradation of corrupt proteins (28, 29, 43) . While elevating Cryab either disaggregates or prevents accumulation of insoluble protein in mice over-expressing wild-type GFAP, it may also chaperone protofilament and tetramer assembly in the soluble pool of GFAP, preventing toxic oligomeric forms (G. Tang, M.D. Perng, R. Friedman, S. Wilk, R. Quinlan, J.E. Goldman, in preparation), similar to those found in other proteinopathies (44) . Alternatively, Cryab has also been shown to block activation of RAS (26), which could disrupt downstream activation of MAP kinase signaling pathways and consequently activation of Nrf2 (45) .
In the most severe of the animal models examined (the combination GFAP Tg ; GFAP þ/R236H mice), elevated expression of Cryab in astrocytes restored the expression of Glt1and prevented terminal seizures. Glutamate transporter expression is altered in several models of neurological disease including ALS, Alzheimer's, Parkinson's and Huntington's disease, as well as epilepsy, stroke and ischemia (33) . Glt1 transcription is directly affected by cellular stress through NF-kB and N-myc binding sites in the transporter gene promoter (46) , and activation of MAP kinase pathways via the stress response may be responsible for transcriptional repression of Glt1 in our model as well. In addition, Glt1 expression is positively regulated by Akt (47), and we have recently shown a reduction of phosphorylated Akt in cells expressing mutant GFAP (48) .
Changes in Cryab and Glt1 expression are common to many of the proteinopathies and may correlate with astrocyte dysfunction and/or gliosis. Huntington's, Parkinson's, spinocerebellar ataxia and ALS all demonstrate non-cell-autonomous pathology in which glial expression of mutant proteins has a toxic effect on vulnerable neurons (49) . Although endogenous Cryab is elevated in AxD (36), astrocyte-specific pathology causes severe neurodegeneration with the loss of cortical white matter eventually leading to death, clearly demonstrating a failed protective response. The rescue effect of overexpressing Cryab to suppress cellular stress and maintain astrocyte functions such as glutamate uptake may have wide-ranging implications in the pathogenesis of protein aggregation disorders, and astroprotection should be investigated as therapeutic strategy not only for AxD but also for other degenerative disorders with glial involvement. With the overall reduction in stress response, proteinopathies outside of the CNS, including familial myopathies and hepatopathies, where Cryab also accumulates, may benefit from a similar approach.
MATERIALS AND METHODS
Transgene construction
To generate an astrocyte-specific aB-crystallin transgene, the human GFAP promoter (50) (position 22163 to þ47) was positioned in front of a 6 kb genomic fragment of the hamster aB-crystallin gene (Cryab) (51) . The transgene includes the translation initiation site with 90 bp of 5 0 -UTR, polyadenylation signal and all three exons of Cryab. Restriction sites within the cloning plasmid linker sequences were used to ligate the GFAP and Cryab fragments together. NotI was used to excise the transgene (Tg141) from the construct vector ( Fig. 2A) .
Mice aB-crystallin transgenic mice were generated by injecting Tg141 into the pronucleus of fertilized FVB/N ova. Founder lines were maintained in the FVB/N background as hemizygotes. GFAP Tg73.7 transgenic (10) and ARE-hPAP reporter mice (52) were generated as described previously and are also bred in the FVB/N background. Cryab 2/2 knockout mice (38) 
Electron microscopy of Rosenthal fibers
Animals were anesthetized and perfused with 10 ml of 0.1 M sodium phosphate buffer, pH 7.4, followed by 50 ml 2.5% glutaraldehyde/2% paraformaldehyde. Brains were removed and post-fixed for 2 h before embedding in Polybed 812. Sections were viewed in a Philips CM120 scanning transmission electron microscope at the University of Wisconsin Medical School Electron Microscopy Facility.
Immunohistochemistry and immunofluorescence
For ubiquitin immunohistochemistry, animals were anesthetized and perfused with 20 ml PBS, brains removed and immersion-fixed in methacarn overnight, paraffin-embedded and sectioned for slides (6 mm 
ARE-hPAP histochemistry and quantitative assay
For alkaline phosphatase histochemistry, animals were perfused with 10 ml PBS, followed by 50 ml 4% paraformaldehyde. Brains were immersion-fixed for 2 h, alcohol-dehydrated, paraffin-embedded and sectioned for slides (6 mm). After de-paraffinizing and rehydration, sections were heated at 658C for 45 min in AP buffer (0.1 M Tris, pH 9.5/0.1 M NaCl/5 mM MgCl 2 ) to inactivate endogenous alkaline phosphatases. Sections were then incubated in AP buffer with 0.17 mg/ml 5-bromo-4-chloro-3-indolyl phosphate (Sigma B6149) for 48 h at 378C. Sections were rinsed, counterstained with eosin, dehydrated and coverslips applied. To quantitate and compare the level of reporter gene activity, half-brain samples (bisected at midline) were homogenized in 1 ml lysate buffer (50 mM Tris -HCl, pH 7.5/ 5 mM MgCl 2 /100 mM NaCl/4% CHAPS) and centrifuged at 17 000g for 20 min at 48C. Supernatants were collected and protein quantified with the BioRad Protein Assay (Hercules, CA, USA). Samples were diluted to 100 ng/ml, 25 ml added to 75 ml 200 mM diethanolamine (DEA) in a microtiter plate and heated for 20 min at 658C to inactivate endogenous alkaline phosphatase activity. At room temperature, 100 ml chemiluminescent substrate CSPD with Emerald enhancer (2Â; Tropix-Applied Biosystems, Bedford, MA, USA) in 5 mM MgCl 2 /150 mM DEA was added to each well, incubated at room temperature for 20 min, and enzyme activity measured with a GloRunner Microplate Luminometer.
Quantitative PCR for stress response transcripts and glutamate transporters Real-time PCR was performed with samples from four mice at P26 for each genotype in the 129SFVBF1 hybrid background. Quantitative PCR was performed as described previously (11 
Statistics
For direct comparisons of transcript and protein levels between relevant genotypes, unpaired two-tailed t-tests were used to generate P-values; for survival curves, log-rank Mantel -Cox analysis. All analyses were performed using GraphPad Prism Software, version 5.01 (San Diego, California, CA, USA).
